Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.

AIDS Africa HIV HIV subtype epidemiology

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
02 07 2019
Historique:
received: 21 09 2018
accepted: 22 03 2019
pubmed: 3 4 2019
medline: 3 4 2019
entrez: 3 4 2019
Statut: ppublish

Résumé

Few human immunodeficiency virus (HIV)-infected persons can maintain low viral levels without therapeutic intervention. We evaluate predictors of spontaneous control of the viral load (hereafter, "viral control") in a prospective cohort of African adults shortly after HIV infection. Viral control was defined as ≥2 consecutively measured viral loads (VLs) of ≤10 000 copies/mL after the estimated date of infection, followed by at least 4 subsequent measurements for which the VL in at least 75% was ≤10 000 copies/mL in the absence of ART. Multivariable logistic regression characterized predictors of viral control. Of 590 eligible volunteers, 107 (18.1%) experienced viral control, of whom 25 (4.2%) maintained a VL of 51-2000 copies/mL, and 5 (0.8%) sustained a VL of ≤50 copies/mL. The median ART-free follow-up time was 3.3 years (range, 0.3-9.7 years). Factors independently associated with control were HIV-1 subtype A (reference, subtype C; adjusted odds ratio [aOR], 2.1 [95% confidence interval {CI}, 1.3-3.5]), female sex (reference, male sex; aOR, 1.8 [95% CI, 1.1-2.8]), and having HLA class I variant allele B*57 (reference, not having this allele; aOR, 1.9 [95% CI, 1.0-3.6]) in a multivariable model that also controlled for age at the time of infection and baseline CD4+ T-cell count. We observed strong associations between infecting HIV-1 subtype, HLA type, and sex on viral control in this cohort. HIV-1 subtype is important to consider when testing and designing new therapeutic and prevention technologies, including vaccines.

Identifiants

pubmed: 30938435
pii: 5425476
doi: 10.1093/infdis/jiz127
pmc: PMC6603968
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-441

Subventions

Organisme : Medical Research Council
ID : MC_UU_00027/1
Pays : United Kingdom
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI051231
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI064060
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
AIDS Res Hum Retroviruses. 2011 Jan;27(1):5-12
pubmed: 21091377
EBioMedicine. 2016 Nov;13:305-314
pubmed: 27751765
AIDS. 1999 Oct 1;13(14):1990-1
pubmed: 10513667
J Infect Dis. 2002 May 1;185(9):1244-50
pubmed: 12001041
AIDS. 2014 Jan 14;28(2):149-62
pubmed: 24149086
PLoS One. 2015 Jan 20;10(1):e0116100
pubmed: 25602351
PLoS One. 2014 Jul 03;9(7):e101475
pubmed: 24992306
J Virol. 2002 Aug;76(16):8276-84
pubmed: 12134033
AIDS. 2009 Nov 27;23(18):2479-84
pubmed: 19841572
AIDS. 2017 Nov 28;31(18):2541-2546
pubmed: 29028659
Pathol Biol (Paris). 2006 Dec;54(10):566-71
pubmed: 17027185
Sci Rep. 2018 Apr 17;8(1):6111
pubmed: 29666450
Hum Genet. 2014 Sep;133(9):1187-97
pubmed: 24969460
AIDS. 2005 Nov 18;19(17):2001-7
pubmed: 16260907
Virology. 2009 Mar 15;385(2):416-24
pubmed: 19157481
Annu Rev Med. 2012;63:131-45
pubmed: 22248321
AIDS. 2014 Jan 14;28(2):235-43
pubmed: 24413311
Sci Rep. 2015 Jun 17;5:11253
pubmed: 26082240
Virology. 2014 Jan 20;449:254-62
pubmed: 24418560
Cell Mol Life Sci. 2013 Mar;70(6):1009-19
pubmed: 22864624
J Virol. 2013 Jan;87(2):708-15
pubmed: 23115285
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
AIDS. 2013 Nov 13;27(17):2775-86
pubmed: 24113395
Science. 2014 Jul 11;345(6193):1254031
pubmed: 25013080
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):394-398
pubmed: 30063647
J Infect Dis. 1999 Jan;179(1):68-73
pubmed: 9841824
Adv Virus Res. 1999;53:71-88
pubmed: 10582095
J Virol. 2016 Jul 11;90(15):6818-6831
pubmed: 27194762
J Virol. 2011 Sep;85(17):8894-902
pubmed: 21715491
PLoS One. 2009;4(2):e4401
pubmed: 19197365
AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):901-10
pubmed: 11461676
J Infect Dis. 2009 Dec 1;200(11):1714-23
pubmed: 19852669
J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):403-8
pubmed: 19214118

Auteurs

Matt A Price (MA)

International AIDS Vaccine Initiative, New York, New York.
Department of Epidemiology and Biostatistics, University of California-San Francisco.

William Kilembe (W)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.

Etienne Karita (E)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.

Mubiana Inambao (M)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.

Eugene Ruzagira (E)

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.

Anatoli Kamali (A)

International AIDS Vaccine Initiative, New York, New York.

Eduard J Sanders (EJ)

Kenyan Medical Research Institute-Wellcome Trust, Kilifi, Nairobi, Kenya.
Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, London, United Kingdom.

Omu Anzala (O)

KAVI Institute of Clinical Research, Nairobi, Kenya.

Eric Hunter (E)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.

Susan Allen (S)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.

Vinodh A Edward (VA)

Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
The Aurum Institute, South Africa.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, South Africa.
Advancing Care and Treatment for TB/HIV, South African Medical Research Council, Johannesburg, South Africa.

Kristin M Wall (KM)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.
Department of Epidemiology, Emory University, Atlanta, Georgia.

Jianming Tang (J)

Department of Medicine, University of Alabama-Birmingham.

Patricia E Fast (PE)

International AIDS Vaccine Initiative, New York, New York.

Pontiano Kaleebu (P)

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.

Shabir Lakhi (S)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.

Gaudensia Mutua (G)

KAVI Institute of Clinical Research, Nairobi, Kenya.

Linda Gail Bekker (LG)

Desmond Tutu HIV Foundation, Cape Town, South Africa.

Ggayi Abu-Baker (G)

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.

Amanda Tichacek (A)

Rwanda Zambia HIV Research Group, Lusaka and Ndola.
Rwanda Zambia HIV Research Group, Zambia and Kigali.
Rwanda Zambia HIV Research Group, Rwanda.
Department of Epidemiology, Emory University, Atlanta, Georgia.

Paramesh Chetty (P)

International AIDS Vaccine Initiative, New York, New York.
International AIDS Vaccine Initiative Human Immunology Laboratory, London, United Kingdom.

Mary H Latka (MH)

The Aurum Institute, South Africa.

Pholo Maenetje (P)

The Aurum Institute, South Africa.

Heeran Makkan (H)

The Aurum Institute, South Africa.

Freddie Kibengo (F)

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.

Fran Priddy (F)

International AIDS Vaccine Initiative, New York, New York.

Jill Gilmour (J)

International AIDS Vaccine Initiative Human Immunology Laboratory, London, United Kingdom.

Classifications MeSH